Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
JCO Oncol Pract. 2022 Jan;18(1):e98-e107. doi: 10.1200/OP.21.00169. Epub 2021 Jul 29.
The COVID-19 pandemic has led to profound changes in clinical research, including remote consent, telehealth, off-site procedures, shipment of therapy, and remote study monitoring. We assessed longitudinal perceptions of these adjustments among clinical research professionals.
We distributed an anonymous survey assessing experiences, perceptions, and recommendations regarding COVID-19-related clinical research adjustments to cancer clinical research office personnel in May 2020 and again in November 2020. Responses were compared using Fisher's exact and Mann-Whitney U tests.
A total of 90 of 102 invited research personnel (88%) responded. Fifty-three (59%) reported participating in both initial and follow-up surveys. The proportion of respondents reporting personal experience with COVID-19-related adjustments increased over time, particularly for remote initial consent (29% 4%), remote reconsent (24% 9%), and remote study monitoring (36% 22%). Perceived impact of COVID-19-related adjustments on data quality ( = .02) and patient experience ( = .002) improved significantly. However, perceived effect on patient safety ( = .02) and respondent's experience ( = .09) became less favorable. Individuals with personal experience with the adjustment were more likely to recommend continuing remote consent (62% 38%; = .04), remote monitoring (69% 45%; = .05), and therapy shipment (67% 35%; = .01) after the COVID-19 pandemic, with nonsignificant trends for off-site diagnostics (44% 24%; = .13) and telehealth visits (66% 45%; = .08).
More than 6 months into the global pandemic, perceptions of COVID-19-related clinical research changes remain favorable. Experienced individuals are more likely to recommend that these changes continue in the future.
新冠疫情大流行导致临床研究发生了深刻变化,包括远程知情同意、远程医疗、场外程序、治疗转运和远程研究监测。我们评估了临床研究专业人员对这些调整的长期看法。
我们在 2020 年 5 月和 2020 年 11 月向癌症临床研究办公室人员分发了一份匿名调查,评估与新冠疫情相关的临床研究调整的经验、看法和建议。使用 Fisher 确切检验和 Mann-Whitney U 检验比较了应答。
共邀请了 102 名研究人员中的 90 名(88%)参加,其中 53 名(59%)报告参加了初始和随访调查。报告个人经历过新冠疫情相关调整的比例随时间增加,特别是远程初始同意(29% 4%)、远程重新同意(24% 9%)和远程研究监测(36% 22%)。新冠疫情相关调整对数据质量( =.02)和患者体验( =.002)的影响明显改善。然而,对患者安全( =.02)和应答者体验( =.09)的影响变得不利。有个人经历过调整的个体更有可能推荐继续远程同意(62% 38%; =.04)、远程监测(69% 45%; =.05)和治疗转运(67% 35%; =.01),场外诊断(44% 24%; =.13)和远程医疗访视(66% 45%; =.08)有不显著的趋势。
在全球大流行超过 6 个月后,对新冠疫情相关临床研究变化的看法仍然是有利的。有经验的个体更有可能推荐未来继续这些变化。